6.42

1.74% +0.11

Ardelyx Inc (ARDX)

Overview News Price History Option Chain Why ARDX Down? Discussions Forecast

Ardelyx Inc stock is currently priced at $6.42, with a 24-hour trading volume of 5.47M. It has seen a +1.74% increased in the last 24 hours and a -13.48% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.33 pivot point. If it approaches the $6.43 resistance level, significant changes may occur.

Previous Close:

$6.31

Open:

$6.35

24h Volume:

5.47M

Market Cap:

$1.49B

Revenue:

$124.46M

Net Income/Loss:

$-66.07M

P/E Ratio:

-53.50

EPS:

-0.12

Net Cash Flow:

$-90.06M

1W Performance:

-0.93%

1M Performance:

-13.48%

6M Performance:

+78.33%

1Y Performance:

+37.77%

1D Range:

$6.30

$6.59

52W Range:

$3.16

$10.13

Ardelyx Inc Stock (ARDX) Company Profile

Name

Ardelyx Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

510-745-1700

Address

34175 Ardenwood Boulevard, Suite 200, Fremont, CA

Employee

Twitter

@ardelyx

Next Earnings Date

2024-05-02

Latest SEC Filings

ARDX's Discussions on Twitter

Ardelyx Inc Stock (ARDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-23	Initiated	Raymond James	Strong Buy
Sep-07-23	Initiated	H.C. Wainwright	Buy
Aug-25-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-03-23	Upgrade	Wedbush	Neutral → Outperform
Nov-17-22	Upgrade	Piper Sandler	Neutral → Overweight
May-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-01-21	Upgrade	Ladenburg Thalmann	Neutral → Buy
Oct-14-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-21-21	Downgrade	Jefferies	Buy → Hold
Jul-20-21	Downgrade	Piper Sandler	Overweight → Neutral
Jul-20-21	Downgrade	Wedbush	Outperform → Neutral
Mar-23-21	Initiated	Wedbush	Outperform
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Oct-20-20	Resumed	Citigroup	Buy
Feb-18-20	Resumed	Jefferies	Buy
Feb-12-20	Initiated	Citigroup	Buy
Feb-10-20	Initiated	Cowen	Outperform
Apr-08-19	Initiated	Piper Jaffray	Overweight
Aug-24-18	Initiated	Jefferies	Buy
Mar-19-18	Resumed	Leerink Partners	Outperform
Nov-29-17	Reiterated	Citigroup	Buy
Nov-22-17	Reiterated	Ladenburg Thalmann	Buy
Oct-17-17	Resumed	Leerink Partners	Outperform
Mar-31-16	Initiated	Ladenburg Thalmann	Buy
Mar-09-16	Initiated	Cantor Fitzgerald	Buy
Mar-03-16	Initiated	Citigroup	Buy

View All

Ardelyx Inc Stock (ARDX) Latest News

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Ardelyx Inc Stock (ARDX) Financials Data

Ardelyx Inc (ARDX) Revenue 2024

ARDX reported a revenue (TTM) of $124.46 million for the quarter ending December 31, 2023, a +138.61% rise year-over-year.

Ardelyx Inc (ARDX) Net Income 2024

ARDX net income (TTM) was -$66.07 million for the quarter ending December 31, 2023, a +1.70% increase year-over-year.

Ardelyx Inc (ARDX) Cash Flow 2024

ARDX recorded a free cash flow (TTM) of -$90.06 million for the quarter ending December 31, 2023, a -28.58% decrease year-over-year.

Ardelyx Inc (ARDX) Earnings per Share 2024

ARDX earnings per share (TTM) was -$0.31 for the quarter ending December 31, 2023, a +35.42% growth year-over-year.

Ardelyx Inc Stock (ARDX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
RAAB MICHAEL	President & CEO	Apr 01 '24	Sale	7.31	1,518	11,097	1,318,433
GRAMMER ELIZABETH A	See Remarks	Mar 20 '24	Sale	7.73	86,000	664,978	312,993
Rosenbaum David P.	Chief Development Officer	Feb 26 '24	Sale	9.20	5,183	47,684	175,936
RAAB MICHAEL	President & CEO	Feb 20 '24	Sale	8.75	22,917	200,439	1,319,951
Rodriguez Susan	Chief Commercial Officer	Feb 20 '24	Sale	8.75	6,928	60,594	452,795
Renz Justin A	Chief Financial Officer	Feb 20 '24	Sale	8.75	5,341	46,714	304,835
Blanks Robert	See Remarks	Feb 20 '24	Sale	8.75	5,017	43,880	368,186
Rosenbaum David P.	Chief Development Officer	Feb 20 '24	Sale	8.75	5,017	43,880	378,985
Williams Laura A	Chief Medical Officer	Feb 20 '24	Sale	8.75	4,803	42,008	380,138
GRAMMER ELIZABETH A	See Remarks	Feb 20 '24	Sale	8.75	4,432	38,764	398,993

Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.